BUSINESS
Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
To read the full story
Related Article
BUSINESS
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
- Sumitomo Files Latuda for Pediatric Schizophrenia in Japan
March 31, 2026
- Servier’s Glioma Drug Voranigo Now Available in Japan
March 31, 2026
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





